We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Transplantation to Treat Heart Diseases (CSHSBMMCTTHD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2010 by Second Affiliated Hospital, School of Medicine, Zhejiang University.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01234181
First Posted: November 4, 2010
Last Update Posted: November 4, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Second Affiliated Hospital, School of Medicine, Zhejiang University
  Purpose
The purpose of this study, is to determine the differences of clinical outcomes between hypoxic pre-treatment group and control group in bone marrow stem cell transplantation (BM-SCT) to treat acute myocardial infarction (AMI); and to evaluate the safety of both treatments. Heart failure patients underwent PCI treatment after AMI and with informed consent, are randomized allocation into hypoxic pre-treated BM-SCT group, normoxic pre-treated BM-SCT group, and control group. Cell resuspension is intracoronary injected into patients receiving coronary angiography, IL-6, CRP, TNF and BNP are detected; echocardiography, cardiac MRI and ECT are analyzed to evaluate heart function and alive myocardial cells. Holter's ECG monitor is employed to observe arrhythmia and embolism. We hypothesize that, by receiving hypoxic pre-treated BM-SCT, impaired heart function will be reversed in heart failure patients.

Condition Intervention
Myocardial Infarction (MI) or Acute Myocardial Infarction (AMI) Procedure: Hypoxia-stressed BMSCs transplantation to cure MI

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Intracoronary Transplantation in Myocardial Infarction and Other Heart Diseases.

Resource links provided by NLM:


Further study details as provided by Second Affiliated Hospital, School of Medicine, Zhejiang University:

Primary Outcome Measures:
  • Heart function [ Time Frame: one year ]

Estimated Enrollment: 100
Study Start Date: November 2010
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BMSCs transplantation Procedure: Hypoxia-stressed BMSCs transplantation to cure MI
Experimental group: intracoronary injection of 10^7 BMSCs Sham Comparator: inject the same volume saline
Sham Comparator: No BMSCs transplantation Procedure: Hypoxia-stressed BMSCs transplantation to cure MI
Experimental group: intracoronary injection of 10^7 BMSCs Sham Comparator: inject the same volume saline

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of acute Myocardial Infarction(within one month);
  • Age under 65;
  • Infarction related wall motion abnormality on echocardiography;
  • Infarction related TIMI flow grades 3 on coronary angiography during cell injection;
  • Informed consent;

Exclusion Criteria:

  • Active infection, or hematopoietic malignancy;
  • Patients have tumor or other lethal diseases;
  • Informed refusal
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01234181


Sponsors and Collaborators
Second Affiliated Hospital, School of Medicine, Zhejiang University
Investigators
Principal Investigator: Jian'an Wang, M.D, Ph.D 2nd Affiliated Hospital, School of Medicine at Zhejiang University
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jian'an Wang / Director, Chief of Heart Center, Second Affiliated Hospital, School of Medicine, Zhejiang University
ClinicalTrials.gov Identifier: NCT01234181     History of Changes
Other Study ID Numbers: SAHZJU CT001
SFDA2010 ( Registry Identifier: State Food and Drug Administration )
First Submitted: November 3, 2010
First Posted: November 4, 2010
Last Update Posted: November 4, 2010
Last Verified: November 2010

Additional relevant MeSH terms:
Infarction
Heart Diseases
Myocardial Infarction
Hypoxia
Ischemia
Pathologic Processes
Necrosis
Cardiovascular Diseases
Myocardial Ischemia
Vascular Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms